Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Price Target at $8.50

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) has received a consensus rating of "Hold" from the seven ratings firms that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $8.50.

A number of research firms have commented on RGLS. Leerink Partners reissued a "market perform" rating and set a $7.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Regulus Therapeutics in a report on Friday, March 14th. Leerink Partnrs downgraded shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Canaccord Genuity Group restated a "hold" rating and set a $11.00 target price (down previously from $28.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Finally, Jones Trading reiterated a "hold" rating and issued a $7.00 price target (down from $8.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th.

Insider Transactions at Regulus Therapeutics

In other news, insider Preston Klassen bought 12,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was bought at an average price of $7.99 per share, with a total value of $95,880.00. Following the completion of the transaction, the insider now directly owns 48,055 shares of the company's stock, valued at approximately $383,959.45. The trade was a 33.28% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.35% of the company's stock.

Hedge Funds Weigh In On Regulus Therapeutics

A number of large investors have recently made changes to their positions in RGLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Regulus Therapeutics by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,345 shares of the biopharmaceutical company's stock worth $67,000 after purchasing an additional 1,644 shares in the last quarter. PEAK6 LLC acquired a new position in Regulus Therapeutics during the 4th quarter valued at about $95,000. Oppenheimer & Co. Inc. purchased a new stake in Regulus Therapeutics in the first quarter valued at about $96,000. Velan Capital Investment Management LP acquired a new stake in Regulus Therapeutics in the fourth quarter worth about $111,000. Finally, AQR Capital Management LLC purchased a new stake in shares of Regulus Therapeutics during the first quarter worth about $120,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Regulus Therapeutics Stock Performance

NASDAQ RGLS traded up $0.01 on Thursday, reaching $8.21. 1,365,456 shares of the stock traded hands, compared to its average volume of 950,992. Regulus Therapeutics has a 12 month low of $0.83 and a 12 month high of $8.35. The company has a market cap of $568.38 million, a price-to-earnings ratio of -11.25 and a beta of 0.35. The company has a fifty day moving average price of $6.40 and a 200-day moving average price of $3.14.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.14. As a group, research analysts anticipate that Regulus Therapeutics will post -0.88 earnings per share for the current fiscal year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.